ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00245388
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : April 23, 2012
Sponsor:
Information provided by:
Bristol-Myers Squibb

Brief Summary:
This is a randomized, double-blind, dose-ranging, placebo-controlled trial to determine the lipid-lowering efficacy and safety of BMS-298585 (muraglitazar) alone in combination with pravastatin in subjects with mixed dyslipidemia.

Condition or disease Intervention/treatment Phase
Dyslipidemia Drug: Muraglitazar Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Trial to Determine the Lipid-Lowering Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
Study Start Date : April 2002
Actual Study Completion Date : July 2002

Resource links provided by the National Library of Medicine

Drug Information available for: Pravastatin




Primary Outcome Measures :
  1. To compare at a .05 level of significance, after 6 weeks of oral administration of double-blind treatment the percent change from baseline to average triglycerides (TG), week 5-6 between 5, 10 and 20 mg

Secondary Outcome Measures :
  1. Percent changes from baseline to average at week 5-6 of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoprotein A1 (ApoA1), and free fatty acid (FFA) levels


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Non-diabetics
  • Serum TG >150 mg/dL and < or = 600 mg/dL
  • Serum LDL-C >130 mg/dL

Exclusion Criteria:

  • Type 1 or type 2 diabetics
  • Fasting plasma glucose >126 mg/dL
  • Treatment with lipid-lowering drugs, unless they can be withdrawn within the following time frame prior to the first qualifying lipid determination (Week 2):

    • Niacin or bile-acid binding agents and HMG CoA reductase inhibitors: 8 weeks
    • Fibrates: 8 weeks
    • Probucol: 1 year
  • History of active liver disease and/or history of thiazolidinedione-related (troglitazone, rosiglitazone, or pioglitazone) liver abnormalities, hepatic dysfunction, or jaundice

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245388


  Hide Study Locations
Locations
United States, Arizona
Local Institution
Phoenix, Arizona, United States
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States
United States, California
Local Institution
Irvine, California, United States
Local Institution
Long Beach, California, United States
Local Institution
Raleigh, California, United States
Local Institution
Roseville, California, United States
Local Institution
Sacramento, California, United States
Local Institution
San Diego, California, United States
Local Institution
Santa Ana, California, United States
United States, Colorado
Local Institution
Longmont, Colorado, United States
United States, Florida
Local Institution
Clearwater, Florida, United States
Local Institution
Cooper City, Florida, United States
Local Institution
Deland, Florida, United States
Local Institution
Inverness, Florida, United States
Local Institution
Longwood, Florida, United States
Local Institution
Pembroke Pines, Florida, United States
Local Institution
Sarasota, Florida, United States
Local Institution
Stuart, Florida, United States
United States, Georgia
Local Institution
Dunwoody, Georgia, United States
Local Institution
Melbourne, Georgia, United States
United States, Illinois
Local Institution
Peoria, Illinois, United States
United States, Indiana
Local Institution
Indianapolis, Indiana, United States
United States, Iowa
Local Institution
Iowa City, Iowa, United States
United States, Kansas
Local Institution
Overland Park, Kansas, United States
Local Institution
Wichita, Kansas, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Louisiana
Local Institution
Marrero, Louisiana, United States
United States, Maryland
Local Institution
Baltimore, Maryland, United States
Local Institution
Bethesda, Maryland, United States
United States, Minnesota
Local Institution
Edina, Minnesota, United States
Local Institution
Minneapolis, Minnesota, United States
United States, Missouri
Local Institution
Kansas City, Missouri, United States
Local Institution
Saint Louis, Missouri, United States
United States, New Jersey
Local Institution
Toms River, New Jersey, United States
United States, New York
Local Institution
Manlius, New York, United States
United States, North Carolina
Local Institution
Hickory, North Carolina, United States
Local Institution
Winston-Salem, North Carolina, United States
United States, Ohio
Local Institution
Columbus, Ohio, United States
United States, Oregon
Local Institution
Bend, Oregon, United States
Local Institution
Hillsboro, Oregon, United States
Local Institution
Portland, Oregon, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
Local Institution
Sellersville, Pennsylvania, United States
Local Institution
Warminster, Pennsylvania, United States
United States, South Carolina
Local Institution
Greer, South Carolina, United States
Local Institution
Mount Pleasant, South Carolina, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
San Angelo, Texas, United States
Local Institution
San Antonio, Texas, United States
United States, Washington
Local Institution
Olympia, Washington, United States
Local Institution
Seattle, Washington, United States
Local Institution
Yakima, Washington, United States
Canada, Ontario
Local Institution
Ottawa, Ontario, Canada
Sponsors and Collaborators
Bristol-Myers Squibb

Additional Information:
ClinicalTrials.gov Identifier: NCT00245388     History of Changes
Other Study ID Numbers: CV168-008
First Posted: October 28, 2005    Key Record Dates
Last Update Posted: April 23, 2012
Last Verified: April 2012

Keywords provided by Bristol-Myers Squibb:
Mixed Dyslipidemia

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Pravastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors